Magrace Camitan, in Shelby Twp, MI - Clinical Nurse Specialist

Magrace Camitan, is a Clinical Nurse Specialist - Long-term Care based in Shelby Twp, Michigan. Magrace Camitan is licensed to practice in Michigan (license number 4704287216) and her current practice location is 13794 21 Mile Rd, Shelby Twp, Michigan. She can be reached at her office (for appointments etc.) via phone at (586) 532-2100.

NPI number for Magrace Camitan is 1700454204 and her current mailing address is 32162 Wellston Dr, Warren, Michigan. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1700454204.

Contact Information

	Magrace Camitan,
	13794 21 Mile Rd, Shelby Twp, MI 48315-4854
	(586) 532-2100
	Not Available

Provider's Profile

Full Name	Magrace Camitan
Gender	Female
Speciality	Clinical Nurse Specialist - Long-term Care
Location	13794 21 Mile Rd, Shelby Twp, Michigan
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1700454204
Provider Enumeration Date: 06/12/2021
Last Update Date: 06/12/2021

Medical Identifiers

Medical identifiers for Magrace Camitan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1700454204	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
364SL0600X	Clinical Nurse Specialist - Long-term Care	4704287216 (Michigan)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Magrace Camitan is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Magrace Camitan, 32162 Wellston Dr, Warren, MI 48093-8438 Ph: () -	Magrace Camitan, 13794 21 Mile Rd, Shelby Twp, MI 48315-4854 Ph: (586) 532-2100

News Archive

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

CooperVision to launch Proclear 1 day multifocal lenses

More than one billion people worldwide have a vision condition called presbyopia(1), which is a natural decrease in the ability of the lens in the eye to change its shape to focus on close objects. We've all seen others struggle with trying to read menus and newspapers. Maybe it has even happened to you.

Parents follow pediatrician advice on administering MMR vaccinations

News stories about an allegedly harmful link between the mumps, measles and rubella vaccine and the onset of autism had little effect on whether U.S. parents immunized their children, according to a review of immunization records and news stories.

Is there an increased risk of other malignancies in patients with renal cell carcinoma?

There have been conflicting reports in the literature regarding the association of other malignancies with renal cell carcinoma (RCC).

Magrace Camitan, - Clinical Nurse Specialist in Shelby Twp, MI